Kihealth Announces Launch of Beta Intercept™, Advancing Real-Time Detection of Diabetes

Next-generation cfDNA assay built on the Kihealth InterceptIQ™ platform expands the potential for earlier detection, dynamic disease monitoring, and precision therapeutic development in diabetes and metabolic disease. ST. AUGUSTINE, Fla., June 5, 2026 /PRNewswire/ -- Kihealth, Inc., a...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.